Barclays’s Amneal Pharmaceuticals AMRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.91M | Buy |
110,363
+25,748
| +30% | +$353K | ﹤0.01% | 2362 |
|
|
2026
Q1 | $1.05M | Sell |
84,615
-276,623
| -77% | -$3.71M | ﹤0.01% | 2731 |
|
|
2025
Q4 | $4.55M | Buy |
361,238
+16,639
| +5% | +$190K | ﹤0.01% | 2288 |
|
|
2025
Q3 | $3.45M | Sell |
344,599
-66,932
| -16% | -$601K | ﹤0.01% | 2471 |
|
|
2025
Q2 | $3.33M | Buy |
411,531
+124,161
| +43% | +$936K | ﹤0.01% | 2447 |
|
|
2025
Q1 | $2.41M | Sell |
287,370
-65,124
| -18% | -$544K | ﹤0.01% | 2488 |
|
|
2024
Q4 | $2.79M | Buy |
352,494
+56,110
| +19% | +$471K | ﹤0.01% | 2650 |
|
|
2024
Q3 | $2.47M | Buy |
296,384
+169,756
| +134% | +$1.33M | ﹤0.01% | 2682 |
|
|
2024
Q2 | $804K | Sell |
126,628
-30,749
| -20% | -$195K | ﹤0.01% | 2734 |
|
|
2024
Q1 | $954K | Sell |
157,377
-74,643
| -32% | -$421K | ﹤0.01% | 3157 |
|
|
2023
Q4 | $1.41M | Buy |
232,020
+175,852
| +313% | +$783K | ﹤0.01% | 3192 |
|
|
2023
Q3 | $237K | Sell |
56,168
-2,979
| -5% | -$11.1K | ﹤0.01% | 3214 |
|
|
2023
Q2 | $183K | Sell |
59,147
-27,846
| -32% | -$59.3K | ﹤0.01% | 3290 |
|
|
2023
Q1 | $121K | Buy |
86,993
+24,451
| +39% | +$48.7K | ﹤0.01% | 4079 |
|
|
2022
Q4 | $124K | Buy |
62,542
+23,286
| +59% | +$52.2K | ﹤0.01% | 4107 |
|
|
2022
Q3 | $79K | Sell |
39,256
-25,429
| -39% | -$71.3K | ﹤0.01% | 3625 |
|
|
2022
Q2 | $205K | Sell |
64,685
-1,060
| -2% | -$3.84K | ﹤0.01% | 3405 |
|
|
2022
Q1 | $273K | Sell |
65,745
-119,278
| -64% | -$528K | ﹤0.01% | 3247 |
|
|
2021
Q4 | $886K | Buy |
185,023
+118,790
| +179% | +$592K | ﹤0.01% | 2901 |
|
|
2021
Q3 | $354K | Buy |
66,233
+41,778
| +171% | +$210K | ﹤0.01% | 3352 |
|
|
2021
Q2 | $124K | Sell |
24,455
-94,713
| -79% | -$538K | ﹤0.01% | 3759 |
|
|
2021
Q1 | $802K | Buy |
119,168
+13,049
| +12% | +$72.3K | ﹤0.01% | 2906 |
|
|
2020
Q4 | $485K | Sell |
106,119
-24,620
| -19% | -$109K | ﹤0.01% | 3249 |
|
|
2020
Q3 | $508K | Sell |
130,739
-13,719
| -9% | -$58.7K | ﹤0.01% | 3223 |
|
|
2020
Q2 | $688K | Buy |
144,458
+20,482
| +17% | +$84.3K | ﹤0.01% | 3067 |
|
|
2020
Q1 | $431K | Sell |
123,976
-16,168
| -12% | -$68.5K | ﹤0.01% | 3708 |
|
|
2019
Q4 | $676K | Buy |
140,144
+72,051
| +106% | +$250K | ﹤0.01% | 4026 |
|
|
2019
Q3 | $198K | Sell |
68,093
-201,546
| -75% | -$703K | ﹤0.01% | 4973 |
|
|
2019
Q2 | $1.93M | Buy |
269,639
+211,562
| +364% | +$2.16M | ﹤0.01% | 2957 |
|
|
2019
Q1 | $823K | Buy |
58,077
+56,751
| +4,280% | +$750K | ﹤0.01% | 3620 |
|
|
2018
Q4 | $18K | Sell |
1,326
-41,625
| -97% | -$750K | ﹤0.01% | 5939 |
|
|
2018
Q3 | $953K | Sell |
42,951
-325,205
| -88% | -$6.84M | ﹤0.01% | 3674 |
|
|
2018
Q2 | $6.04M | Buy |
+368,156
| New | +$6.46M | 0.01% | 1582 |
|
Other funds holding AMRX
TGA
RCMNY
Barclays's AMRX Position: Q2 2026 in Review
Barclays increased its Amneal Pharmaceuticals (AMRX) stake by 30% in Q2 2026, buying an estimated $353K and bringing the position to 110,363 shares worth $1.91M. The position accounts for ﹤0.01% of the portfolio, ranked #2362.
Barclays first reported a position in AMRX in Q2 2018 and has held it in 33 quarters since. The position peaked at $6.04M in Q2 2018. 306 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.
- Barclays held 110,363 shares of Amneal Pharmaceuticals worth $1.91M as of Q2 2026.
- Barclays bought 25,748 Amneal Pharmaceuticals shares in Q2 2026, an estimated $353K.
- Amneal Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #2362 holding.
- Barclays first reported a position in Amneal Pharmaceuticals in Q2 2018 and has held it in 33 quarters since.
- Barclays's Amneal Pharmaceuticals position peaked at $6.04M in Q2 2018.
- 306 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.
Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.